In today’s briefing:
- [Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes
- GUC (3443.TT): Why the Company Did Show a Bit Cautious Attitude with the Market Price?
- China Healthcare Weekly (Dec.8) – Important Trends in Pharma, Big Discount Sale of Equity, Topchoice
[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes
- China’s innovative drug sector remains a liquidity driven sector, as investible choices are limited, which include Akeso and BeiGene as our BUY ideas.
- We also notice positive change in Innovent but opt to keep rating unchanged;
- We upgrade BeiGene from SELL to BUY and maintain SELL on RemeGen, Innovent, JUNSHI and ZaiLab. We discontinued coverage on Legend Biotech.
GUC (3443.TT): Why the Company Did Show a Bit Cautious Attitude with the Market Price?
- On December 8th, GUC reached its daily limit at the closing price, but the company did not consistently demonstrate an agreeable attitude.
- The “AI” is an explicit knowledge for today, while GUC is a company of project based.
- GUC’s monthly revenue decreased by 22.15% YoY in November 2023.
China Healthcare Weekly (Dec.8) – Important Trends in Pharma, Big Discount Sale of Equity, Topchoice
- We summarized some important opportunities and trends that we think would emerge in the pharmaceutical industry in the future.
- Considering the current unfavorable financing situation of Biotech in the domestic primary market, we anticipate that there would be significant discounts in the sale of equity in the future.
- Topchoice has not yet out of trouble. Most of its business diversification could end in failure. It is difficult to support high valuation only by one hospital and one region.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
